Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting

Sarah M. Bartsch,Patrick T. Wedlock,Marie C. Ferguson,Sheryl S. Siegmund,Bruce Y. Lee,Kelly J. O'Shea
DOI: https://doi.org/10.1016/j.amepre.2020.10.022
IF: 6.604
2021-03-01
American Journal of Preventive Medicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>With norovirus vaccine candidates currently under development, now is the time to identify the vaccine characteristics and implementation thresholds at which vaccination becomes cost effective and cost saving in a community setting.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In 2020, a norovirus transmission, clinical, and economics computational simulation model representing different U.S. population segments was developed to simulate the spread of norovirus and the potential impact of vaccinating children aged &lt;5 years and older adults (aged ≥65 years).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Compared with no vaccination, vaccinating preschool-aged children averted 8%–72% of symptomatic norovirus cases in a community, whereas vaccinating older adults averted 2%–29% of symptomatic cases (varying with vaccine efficacy [25%–75%] and vaccination coverage [10%–80%]). Vaccination with a 25% vaccine efficacy was cost effective (incremental cost–effectiveness ratio ≤$50,000 per quality-adjusted life year) when vaccination cost ≤$445 and cost saving at ≤$370 when vaccinating preschool-aged children and ≤$42 and ≤$30, respectively, when vaccinating older adults. With a 50% vaccine efficacy, vaccination was cost effective when it cost ≤$1,190 and cost saving at ≤$930 when vaccinating preschool-aged children and ≤$110 and ≤$64, respectively, when vaccinating older adults. These cost thresholds (cost effective and cost saving, respectively) further increased with a 75% vaccine efficacy to ≤$1,600 and ≤$1,300 for preschool-aged children and ≤$165 and ≤$100 for older adults.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>This study outlines thresholds at which a norovirus vaccine would be cost effective and cost saving in the community when vaccinating children aged &lt;5 years and older adults. Establishing these thresholds can help provide decision makers with targets to consider when developing and implementing a norovirus vaccine.</p>
medicine, general & internal,public, environmental & occupational health
What problem does this paper attempt to address?